

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/P40FB37A027EN.html>

Date: August 2019

Pages: 50

Price: US\$ 3,500.00 (Single User License)

ID: P40FB37A027EN

Abstracts

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2019

SUMMARY

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) pipeline Target constitutes close to 16 molecules. The latest report P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2019, outlays comprehensive information on the P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - P2X purinoceptor 7 is a protein encoded by the P2RX7 gene. It acts as receptor for ATP that acts as a ligand-gated ion channel. It is responsible for ATP-dependent lysis of macrophages through the formation of membrane pores permeable to large molecules. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 1, 3 and 6 respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Genetic Disorders and Gastrointestinal which include indications Epilepsy, Inflammation, Neuropathic Pain (Neuralgia), Breast Cancer, Charcot-Marie-Tooth Disease Type I A, Colorectal Cancer, Depression, Lung Cancer, Multiple Sclerosis, Prostate Cancer, Alzheimer's Disease, Basal Cell Carcinoma (Basal Cell Epithelioma), Bipolar Disorder (Manic Depression), Duchenne Muscular Dystrophy, Hematological Tumor, Inflammatory Bowel Disease, Major Depressive Disorder, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Prostate Cancer, Neuroinflammation, Pain and Solid Tumor.

Furthermore, this report also reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)

The report reviews P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics and enlists all their major and minor projects

The report assesses P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 7 (P2Z Receptor or P2RX7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Overview

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Companies Involved in Therapeutics Development

Affectis Pharmaceuticals AG

Asahi Kasei Pharma Corp

Axxam SpA

Biosceptre International Ltd

Evotec SE

Integral Molecular Inc

Johnson & Johnson

Lead Discovery Center GmbH

MindImmune Therapeutics Inc

MyoTherix Inc

Suven Life Sciences Ltd

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Drug Profiles

AFC-5128 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKP-23494954 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIL-010t - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIL-03s - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIL-06v - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIL-07v - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EVT-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-5446 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-55308942 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Antagonize P2X7 for Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small molecule to Antagonize P2X7 for Multiple Sclerosis and Epilepsy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize P2X7 Receptor for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize P2RX7 for CNS Disorders, Autoimmune Disorders and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize P2X7 for Inflammation and Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize P2X7 for Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Dormant Products

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Discontinued Products

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Product Development Milestones

Featured News & Press Releases

Nov 14, 2018: Update on phase I trial of vaccine BIL06v

Aug 21, 2018: Initiation of Biosceptre's phase 1 clinical trial for first-in-class oncology vaccine BIL06v

Mar 03, 2017: Biosceptre publishes a clinical study of topical drug BIL010t as therapy for Basal cell carcinoma

Dec 18, 2014: Alzheimer's Drug Discovery Foundation And Axxam Continue Their Successful Collaboration To Develop Novel Therapeutics For Alzheimer's Disease

Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma

Jan 25, 2012: Affectis Receives European Patent For AFC-5128 And Other P2X7 Antagonists

Jun 29, 2009: Evotec Announces The Successful Completion Of The First Phase I Study With EVT 401

Oct 09, 2008: Evotec Announces Phase I Initiation With P2X7 Antagonist

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Affectis Pharmaceuticals AG, H2 2019
Pipeline by Asahi Kasei Pharma Corp, H2 2019
Pipeline by Axxam SpA, H2 2019
Pipeline by Biosceptre International Ltd, H2 2019
Pipeline by Evotec SE, H2 2019
Pipeline by Integral Molecular Inc, H2 2019
Pipeline by Johnson & Johnson, H2 2019
Pipeline by Lead Discovery Center GmbH, H2 2019
Pipeline by MindImmune Therapeutics Inc, H2 2019
Pipeline by MyoTherix Inc, H2 2019
Pipeline by Suven Life Sciences Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Affectis Pharmaceuticals AG

Asahi Kasei Pharma Corp

Axxam SpA

Biosceptre International Ltd

Evotec SE

Integral Molecular Inc

Johnson & Johnson

Lead Discovery Center GmbH

MindImmune Therapeutics Inc

MyoTherix Inc

Suven Life Sciences Ltd

I would like to order

Product name: P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/P40FB37A027EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P40FB37A027EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970